TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02257567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine 90 milligrams per meter-squared (mg/m\^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Study: NCT02064946

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: 50,000IU/week of vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03481088

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Functional appliance therapy
Description: All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~1. Stage- I (pre-treatment),~2. Stage- II (after pre-functional therapy)~3. Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)
Study: NCT04602663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Variceal Band ligation
Description: Band ligation of OV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Variceal Band ligation
Description: Band ligation of OV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Variceal Band ligation
Description: Band ligation of OV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Variceal Band ligation
Description: Band ligation of OV
Study: NCT03960749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sprotte 25G needle, stylet reinserted
Description: Lumbar puncture with small bore atraumatic needle, stylet reinserted before needle withdrawal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sprotte 25G needle, stylet not reinserted
Description: Lumbar puncture with small bore atraumatic needle, stylet not reinserted before needle withdrawal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sprotte 22G needle, stylet reinserted
Description: Lumbar puncture with larger bore atraumatic needle, stylet reinserted before needle withdrawal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sprotte 22G needle, stylet not reinserted
Description: Lumbar puncture with larger bore atraumatic needle, stylet not reinserted before needle withdrawal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinocan 25G needle, stylet reinserted
Description: Lumbar puncture with small bore cutting needle, stylet reinserted before needle withdrawal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinocan 25G needle, stylet not reinserted
Description: Lumbar puncture with small bore cutting needle, stylet not reinserted before needle withdrawal
Study: NCT00546806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programs of Care
Description: Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programs of Care
Description: Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Programs of Care
Description: Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
Study: NCT02209714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIF 1149 BS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03626454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine Bolus
Description: 'Norepinephrine Bitartarte' bolus of 6 µg/mL for 30 seconds immediately after intrathecal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine infusion
Description: an infusion of 6 µg/mL norepinephrine that was started at 6 µg/kg/h immediately after intrathecal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: 10 ml normal saline in syringe for bolus for 30 seconds immediately after intrathecal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution
Description: 50 ml syringe with normal saline infuse at a rate 1ml/kg/h immediately after intrathecal injection
Study: NCT03692208

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Diabetes Goal Survey and Optional Care Management
Description: The intervention is already described in the intervention arm description.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Diabetes Goal Survey and Optional Care Management
Description: The intervention is already described in the intervention arm description.
Study: NCT01747447

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo
Description: Vitamin D placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.
Study: NCT00278343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: 30mg given PO, daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04471714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other. During each visit the soleus H-reflex will be measured and conditioned by common peroneal nerve stimulation to assess presynaptic inhibition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Participants will come in for two visits. In a randomized manor, they will receive baclofen on one visit and a placebo on the other. During each visit the soleus H-reflex will be measured and conditioned by common peroneal nerve stimulation to assess presynaptic inhibition.
Study: NCT00755664

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose complex B-vitamins
Description: The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose complex B-vitamins
Description: The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.
Study: NCT02177123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnFocus MicroShunt implantation
Description: Implantation will include the use of Mitomycin C applied with sponges.
Study: NCT00562224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI-24781
Description: Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (TID), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart (BID). If a DLT occurs on the BID schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached.
Study: NCT04665401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored MERIT
Description: see arm description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard MERIT
Description: see arm description
Study: NCT03572517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subarachnoid block
Description: Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) associated with subarachnoid block (bupivacaine and morphine)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal morphine
Description: Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) and spinal analgesia with morphine
Study: NCT00311675

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Description: Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA. Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
Study: NCT01703195

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic Resonance Imaging (MRI) obtained pre-treatment and 4-6 weeks post-treatment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Diffusion Weighted Magnetic Resonance Imaging (DWMR)
Description: Diffusion Weighted Magnetic Resonance Imaging (DWMR) obtained pre-treatment and 4-6 weeks post-treatment.
Study: NCT02273934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reablement
Description: The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: The control intervention is standard home-based treatment/care in Norway.
Study: NCT01280903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR Intervention
Description: The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-Control
Description: Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
Study: NCT02250326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel IV
Description: nab-Paclitaxel intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel IV
Description: nab-Paclitaxel intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel IV
Description: nab-Paclitaxel intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486
Description: Oral CC-486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duravalumab
Study: NCT04199351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 171
Description: 2 SAD cohorts of 8 subjects per cohort randomized 3:1 in Part A; 1 cohort of 8 subjects 3:1 ratio in Part B; and 24 subjects enrolled into 1 of 3 cohorts with 8 subjects randomized to receive 2 to 3 consecutive doses (titration) 3:1 ratio in Part C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 171
Description: 2 SAD cohorts of 8 subjects per cohort randomized 3:1 in Part A; 1 cohort of 8 subjects 3:1 ratio in Part B; and 24 subjects enrolled into 1 of 3 cohorts with 8 subjects randomized to receive 2 to 3 consecutive doses (titration) 3:1 ratio in Part C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 171
Description: 2 SAD cohorts of 8 subjects per cohort randomized 3:1 in Part A; 1 cohort of 8 subjects 3:1 ratio in Part B; and 24 subjects enrolled into 1 of 3 cohorts with 8 subjects randomized to receive 2 to 3 consecutive doses (titration) 3:1 ratio in Part C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: AMG 171 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: AMG 171 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: AMG 171 placebo
Study: NCT02257567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (Liquid)
Description: Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (Liquid)
Description: Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (Liquid)
Description: Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin (Liquid)
Description: Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Study: NCT04132661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 5 milligram
Description: one single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: one single dose
Study: NCT04255719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DBS
Description: Unilateral DBS for treatment of patients with PD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DBS
Description: Unilateral DBS for treatment of patients with PD
Study: NCT01432171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Given PO
Study: NCT04188743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic FMT
Description: Transplantation of fecal microbiota from a donor into a recipient

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Autologous FMT
Description: Transplantation of autologous fecal microbiota
Study: NCT02443688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-4430
Study: NCT02257567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Study: NCT02443688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-4430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01223534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preventive treatment with Isoniazid.
Description: If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preventive treatment with Isoniazid
Description: If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.
Study: NCT00688987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric Diet
Description: Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone
Study: NCT01251965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I.
Study: NCT02257567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab standard dose, 375 mg/m\^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Study: NCT00492999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given by hepatic arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given by hepatic arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Description: Given by hepatic arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Description: Given by hepatic arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV